FDA-cleared profile

Viz CTP

Viz.ai, Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Image processing, analysis, and communication of dynamic brain CT perfusion datasets to calculate perfusion parameters for review by trained professionals.

Clinical role
Standalone CT perfusion post-processing, analysis, and DICOM communication support.
Images and patients
CT/CTA · Brain
Key limitation
Keep in mind: The FDA indication is limited to CT Perfusion datasets and does not include MRI protocols. The packet does not establish a specific clinical care setting or scanner manufacturer; it describes operation on a standard off-the-shelf computer or virtual platform such as VMware.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Image processing, analysis, and communication of dynamic brain CT perfusion datasets to calculate perfusion parameters for review by trained professionals.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain Input: Dynamic brain CT perfusion scans acquired through DICOM-compliant imaging devices.
  • Who uses it?Intended users: Trained professionals including physicians and medical technicians, particularly medical imaging professionals who analyze dynamic CT perfusion studies
  • What does the software produce?Output: Standard DICOM parametric maps for Cerebral Blood Flow (CBF), Cerebral Blood Volume (CBV), Mean Transit Time (MTT), residue-function time-to-peak (TMax), and Arterial Input Function (AIF), viewable on existing radiological imaging viewers.
  • What is its most important limitation?Key limitation: The FDA indication is limited to CT Perfusion datasets and does not include MRI protocols. The packet does not establish a specific clinical care setting or scanner manufacturer; it describes operation on a standard off-the-shelf computer or virtual platform such as VMware.

Clinical takeaway. Clinical role: Image processing, analysis, and communication of dynamic brain CT perfusion datasets to calculate perfusion parameters for review by trained professionals.

Evidence takeaway. Evidence from the reviewed source record: FDA performance testing used a commercially available simulated digital phantom generated from tracer-kinetic theory with clinically relevant perfusion parameters as ground truth. Output correlations with ground truth were compared with seven other commercial or academic CTP software packages, and pre-established goals for AIF detection, soft-matter extraction, CBF, CBV, MTT, and TMax were achieved. The packet reports no sensitivity, specificity, AUC, or clinical outcome endpoint.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Image processing, analysis, and communication of dynamic brain CT perfusion datasets to calculate perfusion parameters for review by trained professionals.
  • Exact FDA submission
  • Checked 2026-09-09
Workflow role
Standalone CT perfusion post-processing, analysis, and DICOM communication support.
  • Exact FDA submission
  • Checked 2026-09-09
Required input
Dynamic brain CT perfusion scans acquired through DICOM-compliant imaging devices.
  • Exact FDA submission
  • Checked 2026-09-09
Output and clinician action
Standard DICOM parametric maps for Cerebral Blood Flow (CBF), Cerebral Blood Volume (CBV), Mean Transit Time (MTT), residue-function time-to-peak (TMax), and Arterial Input Function (AIF), viewable on existing radiological imaging viewers.
  • Exact FDA submission
  • Checked 2026-09-09
Intended users
Trained professionals including physicians and medical technicians, particularly medical imaging professionals who analyze dynamic CT perfusion studies
  • Exact FDA submission
  • Checked 2026-09-09
Limitations
The FDA indication is limited to CT Perfusion datasets and does not include MRI protocols. The packet does not establish a specific clinical care setting or scanner manufacturer; it describes operation on a standard off-the-shelf computer or virtual platform such as VMware.
  • Exact FDA submission
  • Checked 2026-09-09
Evidence summary
FDA performance testing used a commercially available simulated digital phantom generated from tracer-kinetic theory with clinically relevant perfusion parameters as ground truth. Output correlations with ground truth were compared with seven other commercial or academic CTP software packages, and pre-established goals for AIF detection, soft-matter extraction, CBF, CBV, MTT, and TMax were achieved. The packet reports no sensitivity, specificity, AUC, or clinical outcome endpoint.
  • Exact FDA submission
  • Checked 2026-09-09

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA performance testing used a commercially available simulated digital phantom generated from tracer-kinetic theory with clinically relevant perfusion parameters as ground truth. Output correlations with ground truth were compared with seven other commercial or academic CTP software packages, and pre-established goals for AIF detection, soft-matter extraction, CBF, CBV, MTT, and TMax were achieved. The packet reports no sensitivity, specificity, AUC, or clinical outcome endpoint.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Viz CTP regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K180161
  • IndependenceIndependence not established

K180161

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K180161. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Dynamic brain CT perfusion scans acquired through DICOM-compliant imaging devices.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-09 · FDA K180161: Viz CTP

  2. Routing

    Source context, not route validation: The standalone package includes DICOM receiving and sending, study processing, DICOM storage, and system-health monitoring; it can receive data from a modality, local-network node, or PACS, write maps back to the source DICOM, and send results to a preconfigured destination. Specific local PACS/RIS compatibility is not established.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-09 · FDA K180161: Viz CTP

  3. AI processing

    Source context, not route validation: The exact FDA package describes Viz CTP software that runs on a standard off-the-shelf computer or a virtual platform, such as VMware, and can be deployed on a supportive infrastructure that meets the minimum system requirements. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "The software runs on a standard "off-the-shelf" computer or a virtual platform, such as VMware" … "The software allows for repeated use and continuous processing of data and can be deployed on a supportive infrastructure that meets the minimum system requirements.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K180161: Viz CTP

  4. Returned objects

    Source context, not route validation: Standard DICOM parametric maps for Cerebral Blood Flow (CBF), Cerebral Blood Volume (CBV), Mean Transit Time (MTT), residue-function time-to-peak (TMax), and Arterial Input Function (AIF), viewable on existing radiological imaging viewers.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-09 · FDA K180161: Viz CTP

  5. Viewer/worklist/report

    Unresolved route: Standard DICOM parametric maps for Cerebral Blood Flow (CBF), Cerebral Blood Volume (CBV), Mean Transit Time (MTT), residue-function time-to-peak (TMax), and Arterial Input Function (AIF), viewable on existing radiological imaging viewers.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-09 · FDA K180161: Viz CTP

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes Viz CTP software that runs on a standard off-the-shelf computer or a virtual platform, such as VMware, and can be deployed on a supportive infrastructure that meets the minimum system requirements. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The software runs on a standard "off-the-shelf" computer or a virtual platform, such as VMware" … "The software allows for repeated use and continuous processing of data and can be deployed on a supportive infrastructure that meets the minimum system requirements.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The standalone package includes DICOM receiving and sending, study processing, DICOM storage, and system-health monitoring; it can receive data from a modality, local-network node, or PACS, write maps back to the source DICOM, and send results to a preconfigured destination. Specific local PACS/RIS compatibility is not established.
  • Exact FDA submission
  • Checked 2026-09-09
Security
Viz.ai's own news releases say the Viz.ai One platform completed a SOC 2 Type II + HIPAA audit (announced 2024-02-26) and received ISO 27001:2022 plus six other ISO certificates (announced 2024-07-10). These are vendor announcements; the report and certificates were not read, and certificate dates may have lapsed or renewed since.
  • Vendor-wide
  • Checked 2026-10-25

Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.

Training
The 510(k) summary states Viz CTP is an image processing software package to be used by trained professionals, including but not limited to physicians and medical technicians.
  • Exact FDA submission
  • Checked 2026-10-27

User qualification wording only; the summary specifies no training program or training offering for this device.

Monitoring
Viz.ai's trust center states that its assurance program includes continuously monitored controls, SOC 2 Type II coverage that includes the availability criterion for Viz.ai production systems and supporting infrastructure, ISO 22301 business continuity certification to ensure uninterrupted clinical workflows, and ISO 27035 incident management certification.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statements, not attestations. Certificates and audit reports were not read; the trust center names Viz.ai generally and does not scope these commitments to any specific product release; exact-release scope is not established.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for Viz CTP; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K180161
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2018-04-20
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
10Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Care setting: Not publicly available - checked 2026-11-14 - Exact FDA submission

    The exact FDA decision document was reviewed on 2026-11-14 and does not state a care setting or patient population for the subject device. Confirm intended sites and patients with the vendor and local policy.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K180161 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

10 sources - 3 history items

Source ledger

  1. FDA K180161: Viz CTP

    U.S. Food and Drug Administration - Published 2018-04-20 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Viz CTP model card (K180161)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, limitations, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K180161

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

  8. Viz.ai Announces Completion of SOC 2 Type II + HIPAA Audits

    Viz.ai, Inc. - Published 2024-02-26 - Accessed 2026-10-25

    Scope: security

  9. Viz.ai Strengthens Information Security with ISO Certification

    Viz.ai, Inc. - Published 2024-07-10 - Accessed 2026-10-25

    Scope: security

  10. Viz.ai: Trust Center

    Viz.ai - Accessed 2026-10-27

    Scope: security

Research history

  1. K180161 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K242123

Brainomix 360 e-CTA

Brainomix Limited

Authorized purpose: Brainomix 360 e-CTA analyzes adult CTA brain DICOM for vessel visualization and post-processing, including MCA vessel-density asymmetry, contrast/phase context, overlays, and MIP views, for trained clinical review; it is not for mobile diagnosis and its vessel-density asymmetry ratio is limited to the MCA region.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-01-06
FDA-cleared K221564

Brainomix 360 e-ASPECTS

Brainomix Limited

Authorized purpose: Assists clinician assessment of brain abnormalities and ischemic injury by generating an automated ASPECTS score for known MCA/ICA occlusion cases.

Modality
CT/CTA
Anatomy
Brain
Decision
2023-02-23
FDA-cleared K193289

FastStroke, CT Perfusion 4D

GE Medical Systems SCS

Authorized purpose: Analyzes CT data to display head and neck vasculature and CT perfusion to generate regional blood-flow, blood-volume, mean-transit-time, and capillary-permeability images.

Modality
CT/CTA
Anatomy
Brain
Decision
2020-11-12
FDA-cleared K192962

icobrain-ctp

Icometrix NV

Authorized purpose: Analyzes and communicates dynamic CT-perfusion datasets.

Modality
CT/CTA
Anatomy
Brain
Decision
2020-02-28

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history